RxDoctor Payments Data

Elmo Villanueva, MD

Internal Medicine · Rocky Hill, CTNPI 1831110717

Payments from drug & device makers

$752in general payments, 2019–2025

Across 41 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$432
  • Eisai Inc.$109
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$69
  • Exact Sciences$57
  • Astellas Pharma US Inc$28
  • Bayer$23
  • plus $35 from 2 others

What the payments were for

  • Food & beverage$752100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$752 in reported general payments places this provider in the 75th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$32,047
Medicare patients
146
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban479$143,563
JanuviaSitagliptin Phosphate229$100,138
OzempicSemaglutide36$52,666
ProcritEpoetin Alfa11$45,486
JardianceEmpagliflozin167$45,420
XareltoRivaroxaban167$32,001
XifaxanRifaximin39$31,616
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$31,286
FarxigaDapagliflozin Propanediol40$29,543
RybelsusSemaglutide19$27,547
MounjaroTirzepatide18$19,630
MyrbetriqMirabegron56$19,617
TrulicityDulaglutide19$19,104
CaplytaLumateperone Tosylate37$16,026
PrevacidLansoprazole16$15,754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Linzess, Restasis$432$29,66066 claims
Astellas Pharma US IncMyrbetriq$28$19,61756 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$69$16,02637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Rocky Hill

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →